Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride Ion SCHEMBL11497474 | 1.00 | — | — | |
| SCHEMBL2143466 | 0.69 | — | — | |
| SCHEMBL2106867 | 0.69 | — | — | |
| SCHEMBL290157 | 0.65 | TSHR (0.33) | ALDH1A1 | |
| Fluoride SCHEMBL5586589 | 0.64 | — | — | |
| Fluoride SCHEMBL5586586 | 0.64 | — | — | |
| Water SCHEMBL247719 | 0.62 | TSHR (0.31) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3259945 | 0.62 | TSHR (0.31) | ALDH1A1 | |
| SCHEMBL5586588 | 0.62 | TSHR (0.31) | ALDH1A1 | |
| Iodide SCHEMBL10628089 | 0.62 | TSHR (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| WO-2009076166-A2 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | claimed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | claimed |
| EP-2057111-A1 | A LARGE SCALE METHOD FOR THE DEOXOFLUORINATION OF KETONES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-13 | — | — | EP | claimed |
| US-20080269512-A1 | Large Scale Method for the deoxofluorination of ketones | BAYER SCHERING PHARMA AG (DE) | 2008-10-30 | — | — | US | claimed |
| WO-2008022791-A1 | A LARGE SCALE METHOD FOR THE DEOXOFLUORINATION OF KETONES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-28 | — | — | WO | claimed |
| EP-1892231-A1 | A large scale method for the deoxofluorination of ketones | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-02-27 | — | — | EP | claimed |
| EP-0546179-B1 | 4-O-(AMINOGLYCOSYL)- OR 4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXY-5,5-DIFLUOROSTREPTAMINE DERIVATIVE AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU (JP) | 1997-02-12 | — | — | EP | claimed |
| EP-0254268-B2 | Fluorinated nucleosides,their preparation and their pharmaceutical use against AIDS | WELLCOME FOUND (GB) | 1994-01-12 | — | — | EP | claimed |
| EP-0264576-B1 | Delta 23-LL-F28249 compounds | AMERICAN CYANAMID CO (US) | 1993-11-03 | — | — | EP | claimed |
| EP-0546179-A1 | 4-O-(AMINOGLYCOSYL)- OR 4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXY-5,5-DIFLUOROSTREPTAMINE DERIVATIVE AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1993-06-16 | — | — | EP | claimed |
| US-4999429-A | Process for the preparation of α,α,β-1-trifluoro-1-olefinic derivatives | ETHYL CORPORATION (US) | 1991-03-12 | — | — | US | claimed |
| EP-0254268-B1 | FLUORINATED NUCLEOSIDES,THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AGAINST AIDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-09-19 | — | — | EP | claimed |
| EP-0259014-A2 | 5-Deoxy-5-fluorokanamycin B derivatives and processes for the production thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1988-03-09 | — | — | EP | claimed |
| US-4284764-A | Process for the preparation of 5-fluoro-5-deoxy and 5-epi-fluoro-5-deoxy-4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 5-fluoro-5-deoxy and 5-epi-fluoro-5-deoxy derivatives produced thereby | SCHERING CORPORATION (US) | 1981-08-18 | — | — | US | claimed |
| WO-1980000338-A1 | PROCESS FOR PREPARING SIDE CHAIN FLUORINATED VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RES FOUND (US) | 1980-03-06 | — | — | WO | claimed |
| WO-1980000339-A1 | PROCESS FOR PREPARING 1-FLUORINATED VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RES FOUND (US) | 1980-03-06 | — | — | WO | claimed |
| US-4188345-A | FLUORINATION OF A 3,5-CYCLOVITAMIN D COMPOUND WITH A DIALKYLAMINO-SULFUR TRIFLUORIDE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1980-02-12 | — | — | US | claimed |
| JP-9157193-A | — | — | None | — | — | JP | disclosed |
| US-3976691-A | Dialkylaminosulfur trifluorides as fluorinating agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | ALDH1A1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.